Dogwood Therapeutics, Inc.

NASDAQ:DWTX

Biotechnology

Healthcare
$1.52 +2.22%

+$0.04 today

Market cap
$51.12M
Beta
1.76
P/E (TTM)
-0.2
EPS (TTM)
-$0.84
52W Low $1.28High $9.50

Volume 0.12M

Average 0.09M

DWTX Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Dogwood Therapeutics, Inc.NASDAQ: DWTX

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation outflow shrinks to $0

Q1 FY2026 stock-based compensation was $0, compared with $84.47K a year earlier. Trailing-twelve-month stock-based compensation was $271.17K. Over 3 fiscal years it compounded at -15.2% a year.

Context

  • Stock-based compensation increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly stock-based compensation holds near $0 or moves back toward the trailing-twelve-month quarterly average of $67.79K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$355.64K-25.3% YoY
LTMMar 2026
$271.17K-35.7% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year-25.3%——
3-year CAGR-15.2%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
355.64K USD
Year-over-year change
-25.3%
4-year CAGR
+2.4%

Stock-Based Compensation vs competitors

How DWTX compares with its peers on the latest reported figures

  • DWTX's LTM Mar 2026 stock-based compensation of $271.17K is the smallest of the 2 companies compared; the peer median is $729.64K.
  • Its year-over-year change of -35.7% is the lowest of 2, against a peer median of +113.5%.
  • Over three fiscal years its annual growth of -15.2% compares with a peer median of -31.4%.
DWTX Competitors Peer median
Stock-Based Compensation for DWTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EDSAEdesa Biotech, Inc.LTM Mar 2026$729.64K +113.5%-31.4%—
DWTXDogwood Therapeutics, Inc.LTM Mar 2026$271.17K -35.7%-15.2%—
Peer median (excluding DWTX) $729.64K+113.5%-31.4%—

Competitors are the stored peer set for DWTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(15.96M)(12.25M)(5.3M)(12.35M)(34.26M)
Depreciation & Amortization00012.18K2.06K
Deferred Income Tax000(503)221.1K
Stock-Based Compensation322.88K582.66K619.97K476.02K355.64K
Change in Working Capital(52.19K)197.38K(194.45K)(581.27K)(133K)
Accounts Receivables00000
Inventory00000
Accounts Payables270.01K219.3K(461.25K)219.89K(532.61K)
Other Working Capital(322.2K)(21.92K)266.81K(801.16K)399.6K
Other Non-Cash Items0003.65M18.19M
Operating Cash Flow(15.69M)(11.47M)(4.87M)(8.79M)(15.62M)
Capital Expenditures0(3)050
Acquisitions (Net)0003.76M0
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow0003.76M0
Debt Repayment00015.32M3M
Common Stock Issued04.49M1.16M1.38M4.34M
Common Stock Repurchased(295.17K)00(351)0
Dividends Paid00000
Other Financing Activities197.56K000(53.81K)
Financing Cash Flow(97.6K)4.49M1.16M16.7M7.28M
Effect of Forex Changes000(144.59K)10.64K
Net Change in Cash(15.79M)(6.98M)(3.71M)11.53M(8.32M)
Free Cash Flow(15.69M)(11.47M)(4.87M)(8.79M)(15.62M)

Dogwood Therapeutics, Inc.

NASDAQ:DWTX

Intrinsic Alpha fair value

Locked

Current Price

$1.52

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.